How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about serplulimab

Marketing authorisation indication

2.1

Serplulimab (Hetronifly, Accord Healthcare) in combination with carboplatin and etoposide is indicated for 'the first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES-SCLC)'.

Dosage in the marketing authorisation

Price

2.3

The list price of serplulimab is £1,321.83 per 100-mg vial (company submission, June 2025).

2.4

The company has a commercial arrangement, which would have applied if serplulimab had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Hetronifly will be included here when guidance is published.